AN INTERVENTIONAL OPEN-LABEL PHASE IB/II STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 AS MONOTHERAPY AND COMBINATION THERAPY IN ADULT PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

Study Identifier:
C6461013
CT.gov Identifier:
NCT07227012
EudraCT Identifier:
202552352517
EU Trial (CTIS) Number:
2025-523525-17-00
Study Contact Information:
(210) 593-5651 or [email protected]
Will Be Recruiting

Considering participating in a START clinical trial?

Get Started

Study Summary

The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.

To join the study, participants must meet the following conditions:

  • Be 18 years or older.
  • Have locally advanced or metastatic HCC.
  • Is not a candidate for complete surgical or loco-regional therapies.
  • Have not received any whole-body treatment for HCC.

Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given through intravenous (IV) infusions, which means it will be administered directly into a vein. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Liver
Phase
The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
Phase I/II
Sex
Female & Male
Age
18+ years
Study Drug
N/A
Study Status
Indicates the current recruitment status or the expanded access status
Will Be Recruiting

Requirements information
Inclusion criteria
  • * 18 years of age or older at screening.
  • * Locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by AASLD criteria (for patients with cirrhosis). Participants without cirrhosis require histological confirmation of diagnosis.
  • * Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies.
  • * At least 1 measurable (as defined by RECIST 1.1 per investigator) and untreated lesion.
  • * Adequate hepatic, liver, and renal function
  • * No prior systemic therapy for HCC.
  • * ECOG performance status 0 or 1
  • * Child-Pugh Class A
  • Key
Exclusion criteria
  • Moderate or severe ascites.
  • * History of hepatic encephalopathy.
  • * Participants with known active CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression.
  • * Clinically significant risk of hemorrhage or fistula.
  • * Participants with any history of another malignancy within 3 years.
  • * History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
  • * Participants with active autoimmune diseases requiring systemic treatment within the past 2 years.
  • * Clinically significant cardiovascular disease within 6 months prior to the first dose.
  • * Major surgery or severe trauma within 4 weeks prior to the first dose or planned major surgery during the study.
  • * History of severe bleeding tendency or coagulation dysfunction.
  • * History of severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding, including bleeding event due to esophageal and/or gastric varices, within 6 months prior to the first dose.
  • * Participants with acute, chronic or symptomatic infections.
  • * Participants with history of immunodeficiency.

Clinical Study Information for Healthcare Providers

By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.

View Study Information

Study Locations

Location
Investigator
Status
Condition(s) Treated at Site
Location
START Los Angeles
Los Angeles, CA, United States, 90025
Investigator
Navid Hafez
Status
Will Be Recruiting
Condition(s) Treated at Site
Liver